ClinicalTrials.gg
CompletedNCT06744699MESK-1Updated Nov 16, 2026

Assessment of Gastrointestinal Discomfort and Infections in Healthy Term Infants

An observational study in Gastrointestinal Symptoms, Infection and Allergy Symptoms, sponsored by Ausnutria Hyproca B.V.. Completed at 9 sites in 2 countries. Open to participants aged Up to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Ausnutria Hyproca B.V. · Observational

How we know

Updated Nov 16, 2026Now CompletedFirst site in United Arab Emirates+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
106
Ages
Up to 24 Months
Sex
All
01

Study summary

A retrospective observational medical dossier-based study to assess gastrointestinal discomfort and infections in healthy term infants

Read the detailed description

Gastrointestinal (GI) symptoms like regurgitation, unexplained crying and stool issues (diarrhoea or constipation) are common in young infants \<4 months of age due to an immature gut epithelial barrier, immune system and microbiota, with studies indicating prevalences ranging from 25.9%-78%. This retrospective observational medical dossier-based study is designed to determine the occurrence of GI symptoms in healthy term formula-fed infants to confirm reported prevalence of mild GI symptoms by HCPs in Middle East (74%). As a secondary objective, the improvement of confirmed GI symptoms when switched before 4 months of age from a CMF to GMF will be determined. Based on the results of a previous study in infants with confirmed GI symptoms, it is expected that fewer GI symptoms will be scored in medical dossiers of infants after switching from CMF to GMF, with HM as a reference group. Other secondary objectives of this study are to explore differences between healthy term infants that were fed GMF compared to infants fed CMF or HM on immune related outcomes such as infections and allergies, medication use related to infections and/or gastrointestinal discomfort and/or allergies, number of clinic visits, adequate growth and reason of changing infant formula.

02

Conditions studied

  • Gastrointestinal Symptoms
  • Infection
  • Allergy Symptoms
  • Growth

Browse trials for

Keywords

  • infant
  • retrospective
  • medical dossier-based study
  • GI symptoms
  • infection symptoms
  • allergy symptoms
  • type of feeding
  • growth
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's enrollment of 106 is below the median of 300 across 688 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Ausnutria Hyproca B.V. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of 300 healthy term infants with medical dossiers covering the period of 0-12 months of age and at least 6 clinic visits.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Either exclusively formula fed (GMF or CMF; consumption of HM ≤2 weeks is allowed for formula fed infants) OR exclusively breastfed before introduction of complementary feeding.
  • Age 12-24 months of age to ensure collection of recent data.
  • If required by local regulation or guidelines, written (ICF) from Investigator (or parent(s) and/or caregiver(s)* aged ≥18 years).
  • Singleton, term infants (gestational age ≥ 37 weeks and ≤ 42 weeks).
  • At least 6 reported visits to the doctor between 0-12 months of age.

Exclusion criteria

Exclusion Criteria:

  • Consumed hydrolysed infant formula or other specialty formulas.
  • Any current or previous illnesses/conditions and/or known congenital diseases or malformations which could interfere with the study outcomes, as per Investigator's clinical judgement.
  • Participation in any clinical trial during first year of life.
  • For formula-fed infant, no switch in feeding type after 4 months of age is allowed.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
106 participants (actual)
Patient registry
No

Groups and cohorts

  • Formula-fed infants

    Formula-fed infants either goat milk-based infant formula or cow's milk-based infant formula

    Other: Infants fed goat milk-based infant formula

Interventions

  • OtherInfants fed goat milk-based infant formula

    Type of infant feeding during the age of 0-12 months

    Also known as: Infants fed cow's milk based infant formula, Infants breastfed / human milk feeding

06

What researchers measure

Primary outcomes

  1. To investigate the occurrence of symptoms related to GI discomfort in formula-fed infants in the Gulf region

    To determine the number of symptoms related to GI discomfort in formula-fed infants between 0-12 months of age

    Time frame: retrospective infants from 0 - 12 months of age

07

Study locations

9 sites
  • Samir Abbas Hospital
    Jeddah, Saudi Arabia
  • Al Emies hospital
    Jizan, Saudi Arabia
  • Mana GH Jubail
    Jubail, Saudi Arabia
  • ProCare Hospital
    Khobar, Saudi Arabia
  • AlAhmady Hospital
    Madinah, Saudi Arabia
  • Dallah Hospital
    Riyadh, Saudi Arabia
  • Dallah Namar hospital
    Riyadh, Saudi Arabia
  • Al Hada Hospital
    Ta'if, Saudi Arabia
  • Altadawi Medical Hospital
    Garhoud, Dubai, United Arab Emirates
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in Apr 2025, 5 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Feb 2025 → Apr 2025 and completion Feb 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 20, 2024
StartActual
Nov 18, 2024
Primary completionActual
Apr 24, 2025was Feb 2025
CompletionActual
Apr 24, 2025was Feb 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Sites
8 sites added, 2 sites removed — first site in United Arab Emirates
Show 8 added (7 Saudi Arabia, 1 United Arab Emirates)
  • Samir Abbas Hospital · Jeddah, Saudi Arabia
  • Al Emies hospital · Jizan, Saudi Arabia
  • ProCare Hospital · Khobar, Saudi Arabia
  • AlAhmady Hospital · Madinah, Saudi Arabia
  • Dallah Hospital · Riyadh, Saudi Arabia
  • Dallah Namar hospital · Riyadh, Saudi Arabia
  • Al Hada Hospital · Ta'if, Saudi Arabia
  • Altadawi Medical Hospital · Garhoud, Dubai, United Arab Emirates
Show 2 removed
  • Al Emies hospital · Gizan, Saudi Arabia
  • AlAhmady Hospital · Medina, Saudi Arabia
Nov 16, 2026
Primary completion
Feb 2025→Apr 24, 2025 (actual)
Nov 16, 2026
Study completion
Feb 2025→Apr 24, 2025 (actual)
Nov 16, 2026
Enrollment
300 (estimated)→106 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    8 sites added, 2 sites removed — first site in United Arab Emirates
    Show 8 added (7 Saudi Arabia, 1 United Arab Emirates)
    • Samir Abbas Hospital · Jeddah, Saudi Arabia
    • Al Emies hospital · Jizan, Saudi Arabia
    • ProCare Hospital · Khobar, Saudi Arabia
    • AlAhmady Hospital · Madinah, Saudi Arabia
    • Dallah Hospital · Riyadh, Saudi Arabia
    • Dallah Namar hospital · Riyadh, Saudi Arabia
    • Al Hada Hospital · Ta'if, Saudi Arabia
    • Altadawi Medical Hospital · Garhoud, Dubai, United Arab Emirates
    Show 2 removed
    • Al Emies hospital · Gizan, Saudi Arabia
    • AlAhmady Hospital · Medina, Saudi Arabia
    Primary completion Feb 2025→Apr 24, 2025 (now actual)
    Study completion Feb 2025→Apr 24, 2025 (now actual)
    Enrollment 300 (estimated)→106 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06744699
Lead sponsor
Ausnutria Hyproca B.V.
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Nov 18, 2024
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion